We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 197

Application to amend inventorship allowed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2013

By this application, Sega sought an Order amending the named inventors of a patent. The application was uncontested by the respondent who did not file

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2013

The PMPRB has announced a Monitoring and Evaluation Plan for the Major Changes in the Guidelines. CIPO has announced a new PCT-Patent Prosecution

Ontario Court dismisses generic claims for unjust enrichment in s. 8 proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Apotex sued Abbott and Takeda for damages pursuant to s. 8 of the NOC Regulations. As part of the claim, Apotex claimed disgorgement of profits

Court dismisses NOC proceeding for mootness when NOA withdrawn

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to

Trial Judge's findings of anticipation and obviousness upheld on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This is an appeal of a patent infringement decision. The Court found the patent invalid for anticipation and obviousness. The Court of Appeal held

Judicial review brought outside time period and no vested right to NOC

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This decision relates to the consideration by the Minister of Health of Apotex’ submission for a Notice of Compliance (NOC) for omeprazole magnesium

Definition of “innovative drug” does not include variations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2013

Health Canada has announced a Consultation on the new Prescription Drug List. The consultation is open for comment until March 7, 2013. Health Canada has

Impeachment action in respect of expired patent allowed to continue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 17 2012

Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent

Final amount for section 8 damages determined

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 12 2012

The Court had previously provided a judgment, resolving a number of matters in dispute between the parties with respect to the amount of compensation to be paid pursuant to s. 8 of the NOC Regulations (summary here